SCHEMBL15548422

SCHEMBL15548422

Cc1nn(C)c(C)c1S(=O)(=O)N1CCC(=O)CC1

nearest known ligand 0.57

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CHRM5 P08912 1/20 0.53
PROKR1 Q8TCW9 16/20 0.52
FPR2 P25090 13/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13993552 0.79 FPR2 (0.61) ALDH1A1NPSR1PROKR1FPR2
SCHEMBL28777441 0.72 FPR2 (0.57) PROKR1FPR2
SCHEMBL30061041 0.71 FPR2 (0.52) PROKR1FPR2
SCHEMBL4988234 0.70 PROKR1 (0.48) ALDH1A1NPSR1CHRM5PROKR1FPR2
SCHEMBL23596390 0.70 LMNA (0.60) ALDH1A1NPSR1PROKR1FPR2
SCHEMBL15548928 0.70 FPR2 (0.79) ALDH1A1PROKR1FPR2
SCHEMBL23596492 0.70 POLB (0.64) ALDH1A1PROKR1FPR2
SCHEMBL16323937 0.70 PROKR1 (1.00) PROKR1FPR2
SCHEMBL23595903 0.69 KMT2A (0.66) PROKR1FPR2
SCHEMBL15550341 0.69 FPR2 (1.00) PROKR1FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200190059-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2020-06-18 US disclosed
US-10544126-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-01-28 US disclosed
US-20190084962-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2019-03-21 US disclosed
US-10167273-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-01 US disclosed
EP-2855449-B1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2018-03-07 EP disclosed
US-20160376256-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-29 US disclosed
US-9475795-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-25 US disclosed
US-9475795-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-25 US disclosed
CN-104520292-B Sulphonylpiperidine derivant and they are for treating the purposes of disease of front dynein mediation 武田药品工业株式会社 2016-09-14 CN disclosed
US-20150111922-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-23 US disclosed
US-20150111922-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-23 US disclosed
EP-2855449-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed
WO-2013179024-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190084962-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PROKR2 ALDH1A1 2914/4885NPSR1 131/4885CHRM5 700/4885
US-20200190059-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PROKR2 ALDH1A1 2914/4885NPSR1 131/4885CHRM5 700/4885
US-10544126-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases PROKR1, GIPR, PROKR2 ALDH1A1 2914/4885NPSR1 131/4885CHRM5 700/4885
US-20160376256-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PROKR2 ALDH1A1 2914/4885NPSR1 131/4885CHRM5 700/4885
US-10167273-B2 Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases PROKR1, GIPR, PROKR2 ALDH1A1 2914/4885NPSR1 131/4885CHRM5 700/4885
US-20150111922-A1 SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES PROKR1, GIPR, PGC ALDH1A1 4158/4885NPSR1 19/4885CHRM5 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.